Headache Disorders
Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatmen...
Сохранить в:
| Формат: | Online |
|---|---|
| Язык: | английский |
| Опубликовано: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| Предметы: | |
| Online-ссылка: | ONIX_20250812T110751_9783725843473_444 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
| _version_ | 1869515616301350912 |
|---|---|
| collection | Directory of Open Access Books |
| description | Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. |
| format | Online |
| id | doab-20.500.12854ir-165689 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1656892025-08-12T10:07:18Z Headache Disorders Argyriou, Andreas A. Michail, Vikelis Dermitzakis, Emmanouil V. CGRP monoclonal antibodies fremanezumab phenotypes predictors response episodic migraine chronic migraine psychiatric comorbidities efficacy headache migraine telehealth virtual care coaching migraine with aura (MA) migraine without aura (MO) familial hemiplegic migraine (FHM) genetics carbonic anhydrase inhibitors idiopathic intracranial hypertension transverse sinuses quality of life questionnaire desvenlafaxine prophylaxis pain women episodes frequency severity disability atogepant CGRP receptor antagonist preventive treatment telecoaching adapted physical activity exercise digital tools COVID-19 lifestyle changes thema EDItEUR::M Medicine and Nursing Four anti-CGRP MAbs are currently in use for the prevention of episodic and chronic migraine: erenumab, which targets the CGRP receptor, and fremanezumab, galcanezumab, and eptinezumab, which target the CGRP ligand. In addition, anti-CGRP MAbs have shown some degree of success as preventive treatments for other headache disorders, such as cluster and post-traumatic headaches. There are, however, unmet needs associated with the prophylactic management of these headache disorders, because of inadequate headache frequency reduction in about one-third of migraine patients and an even higher percentage of treatment failure in cluster and post-traumatic headache patients. Significant unmet needs are also present in the symptomatic management of these headache disorders. To overcome these challenges, new acute pharmacological options for headaches have been studied in the last few years, including gepants, a class of small molecules that target the CGRP receptor, and ditans, a class of non-triptan serotonin receptor antagonists. Gepants have been also explored for migraine prevention. This Special Issue summarizes our existing knowledge on the advantages and limitations of modern therapies for headache disorders, highlights open clinical and pathogenetic issues, and explores future directions for research. The Co-Editors and I are confident that it will serve as a reference point for those seeking to understand why, when, and how to treat headache patients with monoclonal antibodies that target CGRP, gepants or ditans. 2025-08-12T10:07:15Z 2025-08-12T10:07:15Z 2025 book ONIX_20250812T110751_9783725843473_444 9783725843473 9783725843480 https://directory.doabooks.org/handle/20.500.12854/165689 eng image/jpeg Attribution 4.0 International https://mdpi.com/books https://mdpi.com/books/pdfview/book/11038 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-4348-0 10.3390/books978-3-7258-4348-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725843473 9783725843480 120 open access |
| spellingShingle | CGRP monoclonal antibodies fremanezumab phenotypes predictors response episodic migraine chronic migraine psychiatric comorbidities efficacy headache migraine telehealth virtual care coaching migraine with aura (MA) migraine without aura (MO) familial hemiplegic migraine (FHM) genetics carbonic anhydrase inhibitors idiopathic intracranial hypertension transverse sinuses quality of life questionnaire desvenlafaxine prophylaxis pain women episodes frequency severity disability atogepant CGRP receptor antagonist preventive treatment telecoaching adapted physical activity exercise digital tools COVID-19 lifestyle changes thema EDItEUR::M Medicine and Nursing Headache Disorders |
| title | Headache Disorders |
| title_full | Headache Disorders |
| title_fullStr | Headache Disorders |
| title_full_unstemmed | Headache Disorders |
| title_short | Headache Disorders |
| title_sort | headache disorders |
| topic | CGRP monoclonal antibodies fremanezumab phenotypes predictors response episodic migraine chronic migraine psychiatric comorbidities efficacy headache migraine telehealth virtual care coaching migraine with aura (MA) migraine without aura (MO) familial hemiplegic migraine (FHM) genetics carbonic anhydrase inhibitors idiopathic intracranial hypertension transverse sinuses quality of life questionnaire desvenlafaxine prophylaxis pain women episodes frequency severity disability atogepant CGRP receptor antagonist preventive treatment telecoaching adapted physical activity exercise digital tools COVID-19 lifestyle changes thema EDItEUR::M Medicine and Nursing |
| topic_facet | CGRP monoclonal antibodies fremanezumab phenotypes predictors response episodic migraine chronic migraine psychiatric comorbidities efficacy headache migraine telehealth virtual care coaching migraine with aura (MA) migraine without aura (MO) familial hemiplegic migraine (FHM) genetics carbonic anhydrase inhibitors idiopathic intracranial hypertension transverse sinuses quality of life questionnaire desvenlafaxine prophylaxis pain women episodes frequency severity disability atogepant CGRP receptor antagonist preventive treatment telecoaching adapted physical activity exercise digital tools COVID-19 lifestyle changes thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20250812T110751_9783725843473_444 |